FLSM
AKRO

Frazier Life Sciences Management’s Akero Therapeutics AKRO Stock Holding History

Frazier Life Sciences Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-366,784
Closed -$17.4M – 42
2025
Q3 		$17.4M Hold
366,784
– – 0.52% 31
2025
Q2 		$19.6M Buy
+366,784
New +$16.7M 0.78% 27

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Frazier Life Sciences Management's AKRO Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 366,784 shares — an estimated $17.4M sold.

Frazier Life Sciences Management first reported a position in AKRO in Q2 2025 and held it in 2 quarters. The position peaked at $19.6M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Frazier Life Sciences Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 366,784 Akero Therapeutics shares in Q4 2025, an estimated $17.4M.
  • Frazier Life Sciences Management first reported a position in Akero Therapeutics in Q2 2025 and held it in 2 quarters.
  • Frazier Life Sciences Management's Akero Therapeutics position peaked at $19.6M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.